[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Opus Genetics Inc (IRD)

Opus Genetics Inc (IRD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 304,971
  • Shares Outstanding, K 82,648
  • Annual Sales, $ 14,200 K
  • Annual Income, $ -49,590 K
  • EBIT $ -51 M
  • EBITDA $ -51 M
  • 60-Month Beta 0.59
  • Price/Sales 22.41
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 283.44% (-74.33%)
  • Historical Volatility 64.10%
  • IV Percentile 66%
  • IV Rank 18.32%
  • IV High 1,405.35% on 03/11/26
  • IV Low 31.89% on 09/16/25
  • Expected Move (DTE 18) 1.66 (45.66%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 1,526
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 31,979
  • Open Int (30-Day) 14,224
  • Expected Range 1.97 to 5.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.14
  • Number of Estimates 8
  • High Estimate $-0.08
  • Low Estimate $-0.19
  • Prior Year $-0.12
  • Growth Rate Est. (year over year) -16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.53 +2.98%
on 08/07/26
4.42 -17.87%
on 08/25/26
-0.08 (-2.16%)
since 07/31/26
3-Month
2.82 +28.72%
on 07/24/26
4.68 -22.35%
on 06/04/26
-0.73 (-16.74%)
since 05/29/26
52-Week
1.17 +210.26%
on 08/29/25
5.81 -37.52%
on 04/17/26
+2.44 (+205.04%)
since 08/28/25

Most Recent Stories

More News
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19,...

LGVN : 7.00 (+4.17%)
DERM : 7.37 (-1.34%)
IRD : 3.61 (-2.17%)
LGVNR : 0.0005 (-37.50%)
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IRD : 3.61 (-2.17%)
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness...

IRD : 3.61 (-2.17%)
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

OPGx-BEST1 Cohort 1 Topline Data Expected in Second Week of September 2026 Enrollment Completed in LCA5 Registrational Trial with Dosing Planned for Q4 2026 RDH12, MERTK and RHO Programs Advancing...

IRD : 3.61 (-2.17%)
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

IRD : 3.61 (-2.17%)
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Topline six-month efficacy data expected by end of 2027 Phase 3 study follows FDA alignment on registrational trial design through Rare Disease Evidence Principles (RDEP) program Opus Genetics...

IRD : 3.61 (-2.17%)
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease...

IRD : 3.61 (-2.17%)
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results ...

IRD : 3.61 (-2.17%)
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company...

IRD : 3.61 (-2.17%)
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease

Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study design FDA indicates Opus Genetics may submit a BLA based on 6-month efficacy data, with 12-month durability data provided...

IRD : 3.61 (-2.17%)

Business Summary

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills,...

See More

Key Turning Points

3rd Resistance Point 4.05
2nd Resistance Point 3.96
1st Resistance Point 3.82
Last Price 3.61
1st Support Level 3.59
2nd Support Level 3.50
3rd Support Level 3.36

See More

52-Week High 5.81
Fibonacci 61.8% 4.04
Last Price 3.61
Fibonacci 50% 3.49
Fibonacci 38.2% 2.94
52-Week Low 1.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.